{
  "abstract": "The 2024 European Society of Cardiology (ESC) Guidelines on elevated blood pressure (BP) and hypertension reflect a shift from binary thresholds towards a risk-based management approach that aims to reflect the continuous relationship between BP and cardiovascular disease (CVD).1 2 Specifically, rather than providing treatment recommendations based solely on a binary hypertension threshold of BP ≥140/90 mm Hg, the 2024 ESC Guidelines expand treatment recommendations to a broader range of adults who benefit from BP lowering. To this end, the ESC endorses the following categorisation of BP: (1) Non-elevated (office BP <120/70 mm Hg) for which drug treatment is not recommended; (2) Elevated (120–139/70–89 mm Hg) for which drug treatment is recommended based on high CVD risk and follow-up systolic BP level ≥130 mm Hg after 3 months of lifestyle intervention; and (3) Hypertension (≥140/90 mm Hg) for which prompt confirmation and drug treatment are recommended in most individuals.1",
  "authors": [
    {
      "affiliations": [
        "National Institute for Preventative Cardiology, National University of Ireland Galway School of Medicine, Galway, Ireland"
      ],
      "name": "James M G Curneen"
    },
    {
      "affiliations": [
        "National Institute for Preventative Cardiology, National University of Ireland Galway School of Medicine, Galway, Ireland",
        "Department of Epidemiology and the Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA"
      ],
      "name": "John William McEvoy"
    }
  ],
  "title": "Insights from Norway on implementing the 2024 European Society of Cardiology Guidelines for elevated blood pressure and hypertension",
  "uid": "190e3cd9-8aed-56c1-8f2b-0f029321ad5c"
}